Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma.

Marion Eveillard,Even H Rustad,Mikhail Roshal,Yanming Zhang,Amanda Ciardiello,Neha Korde,Malin Hultcrantz,Hani Hassoun,Eric L. Smith,Alexander M. Lesokhin,Sham Mailankody,Carl Ola Landgren,Katie L. Thoren

Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma.

2019

Marion Eveillard
Even H Rustad
Mikhail Roshal
Yanming Zhang
Amanda Ciardiello
Neha Korde
Malin Hultcrantz
Hani Hassoun
Eric L. Smith
Alexander M. Lesokhin
Sham Mailankody
Carl Ola Landgren
Katie L. Thoren

e19525Background: Minimal residual disease (MRD) negativity after completed therapy is associated with longer progression-free survival (PFS) in patients with multiple myeloma (MM). Current standar...

Keywords:

Peripheral
Pathology
MALDI-TOF Mass Spectrometry
Negativity effect
Minimal residual disease
Medicine
Multiple myeloma
peripheral blood
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations